Chongqing Primary Aldosteronism Study

Recruiting now

Conditions studied: Primary Aldosteronism

In brief

We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.

Key facts

Study ID

NCT03224312

Run by

Chongqing Medical University

People needed

1500

Starts

2016-10-01

Expected to finish

2028-12-31

Last updated by the study team

2023-09-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• hypertensive patients who completed ARR screening and necessary further tests;
• Voluntary to sign the informed consent.

You may not qualify if…

• patients with severe cardiac, hepatic or renal dysfunction;
• suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.

Where it is running

• Qifu Li — Chongqing, Chongqing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.